Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice
The efficacy and safety of Dur + Tre in clinical practice were comparable to those reported in a recent phase III trial. The first-line Dur + Tre therapy had a higher DCR than that of the later lines, and the transition rate to second-line therapy was considerably high, suggesting that Dur + Tre therapy would be more beneficial in first-line treatment.
Authors
- Joji Tani (ORCID: https://orcid.org/0000-0001-8801-2505)
- Hironori Tanaka (ORCID: https://orcid.org/0000-0003-4712-0192)
- Masahiro Sogabe (ORCID: https://orcid.org/0000-0002-8214-1354)
- Yasushi Sato (ORCID: https://orcid.org/0000-0002-6776-4609)
- Tetsuji Takayama (ORCID: https://orcid.org/0000-0002-0175-1573)
- Tetsu Tomonari (ORCID: https://orcid.org/0000-0002-8484-9866)
- Yutaka Kawano (ORCID: https://orcid.org/0000-0002-2256-0776)
- Hiroshi Miyamoto (ORCID: https://orcid.org/0000-0002-3715-8894)
- Koichi Okamoto (ORCID: https://orcid.org/0000-0003-0961-1791)
- Akihiro Morishita
Institutions
- Kagawa University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- JGH Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/jgh3.70033
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.48